Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0393754 (HSA)
 2,996 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The Hodgkin's-like Type B neoplasms which arise spontaneously in aging C57L mice (25% incidence at 21 months of age) were first reported over 40 years ago, but since then relatively little has been published about these lymphomas. Based on previous studies in SJL mice, we investigated the phenotypic and functional properties of C57L-derived lymphomas in relation to Mtv29-encoded vSAg expression by the tumor cells, and their ability to stimulate TCR Vbeta-restricted T cells. The cell surface phenotype of the C57L lymphomas indicates a B cell origin (sIg(+), MHC II(+)). These B lymphoma cells also express co-stimulatory molecules [B7-1 (CD80) and HSA (CD24)], and stimulate marked proliferation of syngeneic CD4(+) T cells. C57L B lymphoma cells exhibit Mtv-encoded mRNA by northern analysis, and also stimulate IL-2 production from Vbeta16(+) T cell hybrids, suggesting a role for Mtv 29 in this syngeneic T cell response. After transfer to syngeneic recipients, primary C57L lymphomas grow slowly, if at all. However, tumor growth is greatly accelerated by pretreatment of C57L recipients with anti-asialo GM1 antibody (but not anti-CD8 mAb), suggesting that NK cells play a major role in inhibiting lymphoma growth. If, in addition to anti-asialo GM1, the mice are also pretreated with anti-CD4 mAb, tumor growth is markedly inhibited, indicating that the lymphoma-responsive syngeneic CD4(+) T cells promote tumor growth. Therefore, although the vSAg-induced response stimulated by vSAg29 expressing lymphoma cells in syngeneic TCR Vbeta-restricted CD4(+) T cells is an important etiologic factor in this type of B cell neoplasm both in C57L and in SJL mice, the final outcome of the spontaneous neoplastic process appears strongly influenced by endogenous NK activity in aging mice.
 ...
PMID:B cell lymphomas of C57L/J mice; the role of natural killer cells and T helper cells in lymphoma development and growth. 1097 82

Starch microparticles, an effective adjuvant for oral vaccination in mice, are taken up over the follicle-associated epithelium (FAE) in Peyer's patches when human serum albumin is conjugated to the particles (HSAmp). When recombinant cholera toxin B subunit (rCTBmp) is conjugated, they are taken up over both the FAE and the villus epithelium. This study investigated the effects of the different targeting on the immune response by using particles with both HSA and rCTB (HSA/rCTBmp). The response induced after oral immunisation with this formulation in mice was compared with that obtained after administration of HSAmp, rCTBmp or both given concomitantly (HSAmp+rCTBmp) and after subcutaneous administration. Both the HSA- and rCTB-specific responses were followed quantitatively (as assessed by the anti-[IgM+IgG] level, the s-IgA response and the delayed-type hypersensitivity [DTH] response), or qualitatively (by the IgG subclass profile). After subcutaneous administration, the rCTB-specific IgM+IgG and DTH responses were lower after HSA/rCTBmp than after rCTBmp and the HSA-specific subclass ratio (IgG1/IgG2a+IgG2b) was lower with HSAmp+rCTBmp (but not with HSA/rCTBmp) compared to HSAmp. However, no quantitative and qualitative differences in the immune response after oral administration were detected when rCTB was added to HSAmp. The results indicate that only the uptake over the Peyer's patches decides the immune responses after oral administration and that the increased targeting to GM1 receptors of the villus epithelium does not affect the immune response. Moreover, the qualitative Th1/Th2-balance is controlled by the inherent properties of the antigens in the microparticles upon subcutaneous administration. Thus, the obtained information is important for designing oral microparticulate vaccines in order to obtain the wanted immune response.
 ...
PMID:Starch microparticles as a vaccine adjuvant: only uptake in Peyer's patches decides the profile of the immune response. 1651 26